Search

Your search keyword '"Zalcman G"' showing total 347 results
Start Over Author "Zalcman G" Search Limiters Available in Library Collection
347 results on '"Zalcman G"'

1. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

Author

Zemanová, M., Besse, B., Bonnet, C., Cadranel, J., Chouaid, C., Cortot, A., Debieuvre, D., Delclaux, B., Denis, F., Duchemann, B., El Kouri, C., Ferrand, F.R., Ginoux, M., Hilgers, W., Madroszyk, A., Masson, P., Mazieres, J., Molinier, O., Moro-Sibilot, D., Pichon, E., Mascaux, C., Robinet, G., Roch, B., Zalcman, G., Schmidtke-Schrezenmeier, G., Schuette, W., Urban, L., Gottfried, M., Nechushtan, H., Peled, N., Wollner, M., Zer, A., Baldini, E., Bonanno, L., Bonetti, A., Cappuzzo, F., Delmonte, A., Galetta, D., Maio, M., Minotti, V., Rea, A., Romano, G., Tassinari, D., Tonini, G., Dziadziuszko, R., Karaszewska, B., Szczęsna, A., Cobo, M., De Castro, J., Felip, E., Garcia Campelo, M.R., Hernández, A., Moran, T., Provencio, M., Viteri, S., Dasgupta, A., Gabrail, N., Giaccone, G., Harshad, A., Liu, S., Oubre, D., Panikkar, R., Razaq, M., Sanborn, R., Garcia Campelo, R., Remon, J., Costantini, D., and Vasseur, B.

Published
2023
Full Text
View/download PDF

2. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

Author

Mazieres, J, Drilon, A, Lusque, A, Mhanna, L, Cortot, AB, Mezquita, L, Thai, AA, Mascaux, C, Couraud, S, Veillon, R, Van den Heuvel, M, Neal, J, Peled, N, Früh, M, Ng, TL, Gounant, V, Popat, S, Diebold, J, Sabari, J, Zhu, VW, Rothschild, SI, Bironzo, P, Martinez-Marti, A, Curioni-Fontecedro, A, Rosell, R, Lattuca-Truc, M, Wiesweg, M, Besse, B, Solomon, B, Barlesi, F, Schouten, RD, Wakelee, H, Camidge, DR, Zalcman, G, Novello, S, Ou, SI, Milia, J, and Gautschi, O

Subjects
Lung, Cancer, Clinical Research, Clinical Trials and Supportive Activities, Lung Cancer, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Good Health and Well Being, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, B7-H1 Antigen, Biomarkers, Tumor, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Oncogenes, Programmed Cell Death 1 Receptor, Progression-Free Survival, Registries, Response Evaluation Criteria in Solid Tumors, Retrospective Studies, immunotherapy, lung cancer, oncogenic addiction, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundAnti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely used to treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of ICI across NSCLC harboring oncogenic alterations is poorly characterized. The aim of our study was to address the efficacy of ICI in the context of oncogenic addiction.Patients and methodsWe conducted a retrospective study for patients receiving ICI monotherapy for advanced NSCLC with at least one oncogenic driver alteration. Anonymized data were evaluated for clinicopathologic characteristics and outcomes for ICI therapy: best response (RECIST 1.1), progression-free survival (PFS), and overall survival (OS) from ICI initiation. The primary end point was PFS under ICI. Secondary end points were best response (RECIST 1.1) and OS from ICI initiation.ResultsWe studied 551 patients treated in 24 centers from 10 countries. The molecular alterations involved KRAS (n = 271), EGFR (n = 125), BRAF (n = 43), MET (n = 36), HER2 (n = 29), ALK (n = 23), RET (n = 16), ROS1 (n = 7), and multiple drivers (n = 1). Median age was 60 years, gender ratio was 1 : 1, never/former/current smokers were 28%/51%/21%, respectively, and the majority of tumors were adenocarcinoma. The objective response rate by driver alteration was: KRAS = 26%, BRAF = 24%, ROS1 = 17%, MET = 16%, EGFR = 12%, HER2 = 7%, RET = 6%, and ALK = 0%. In the entire cohort, median PFS was 2.8 months, OS 13.3 months, and the best response rate 19%. In a subgroup analysis, median PFS (in months) was 2.1 for EGFR, 3.2 for KRAS, 2.5 for ALK, 3.1 for BRAF, 2.5 for HER2, 2.1 for RET, and 3.4 for MET. In certain subgroups, PFS was positively associated with PD-L1 expression (KRAS, EGFR) and with smoking status (BRAF, HER2).Conclusions: ICI induced regression in some tumors with actionable driver alterations, but clinical activity was lower compared with the KRAS group and the lack of response in the ALK group was notable. Patients with actionable tumor alterations should receive targeted therapies and chemotherapy before considering immunotherapy as a single agent.

Published
2019

5. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

Author

Stahel, R., Hiltbrunner, A., Pardo-Contreras, M., Gasca-Ruchti, A., Giacomelli, N., Kammler, R., Marti, N., Pfister, R., Piguet, A.C., Roux, S., Troesch, S., Schneider, M., Schweri, R., Zigomo, I., Tsourti, Z., Zygoura, P., Tsouprou, S., Kassapian, M., Vervita, K., Dimopoulou, G., Andriakopoulou, C., Morin, F., Amour, E., Mariaule, G., Archirel, N., Fernandez, M., Pereira, E., Benito, L., Lopez, K., Hernández, A., Chinchen, S., Jurkovic, H., Livingstone, A., Mitchell, J., Walker, M., Mitchell, P., Ng, S., Steer, C., Briscoe, K., Saqib, A., Abdi, E., Houghton, B., O’Byrne, K., Chittajallu, B.R., Hughes, B.G., Black, A., Nackaerts, K., Werner, H., Gervais, R., Zalcman, G., Vaylet, F., Merle, P., Monnet, I., Moro-Sibilot, D., Molinier, O., Girard, N., Souquet, P.-J., Barlesi, F., Debieuvre, D., Senellart, H., Poudenx, M., Dixmier, A., Pouessel, D., Cadranel, J., Lena, H., Quoix, E., Friard, S., Audigier-Valette, C., Mazieres, J., Pichon, E., Faehling, M., Kokowski, K., Kirchen, H., Griesinger, F., Tufman, A., De-Colle, C., de Langen, J., González Larriba, J.L., Insa, A., Majem, M., Massutí, B., Pulla, M.P., Aix, S.P., Villanueva, N., Vivanco, G.L., Andrade, J., Curioni-Fontecedro, A., Franks, K., Califano, R., Peters, S., Pujol, J.-L., Dafni, U., Dómine, M., Popat, S., Reck, M., Becker, A., Insa Mollá, A., López Vivanco, G., Madelaine, J., Provencio Pulla, M., Roschitzki-Voser, H., Ruepp, B., Stahel, R.A., Le Pechoux, C., and De Ruysscher, D.

Published
2022
Full Text
View/download PDF

9. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

Author

Besse, B., primary, Felip, E., additional, Garcia Campelo, R., additional, Cobo, M., additional, Mascaux, C., additional, Madroszyk, A., additional, Cappuzzo, F., additional, Hilgers, W., additional, Romano, G., additional, Denis, F., additional, Viteri, S., additional, Debieuvre, D., additional, Galetta, D., additional, Baldini, E., additional, Razaq, M., additional, Robinet, G., additional, Maio, M., additional, Delmonte, A., additional, Roch, B., additional, Masson, P., additional, Schuette, W., additional, Zer, A., additional, Remon, J., additional, Costantini, D., additional, Vasseur, B., additional, Dziadziuszko, R., additional, Giaccone, G., additional, Zemanová, M., additional, Besse, B., additional, Bonnet, C., additional, Cadranel, J., additional, Chouaid, C., additional, Cortot, A., additional, Delclaux, B., additional, Duchemann, B., additional, El Kouri, C., additional, Ferrand, F.R., additional, Ginoux, M., additional, Mazieres, J., additional, Molinier, O., additional, Moro-Sibilot, D., additional, Pichon, E., additional, Zalcman, G., additional, Schmidtke-Schrezenmeier, G., additional, Urban, L., additional, Gottfried, M., additional, Nechushtan, H., additional, Peled, N., additional, Wollner, M., additional, Bonanno, L., additional, Bonetti, A., additional, Minotti, V., additional, Rea, A., additional, Tassinari, D., additional, Tonini, G., additional, Karaszewska, B., additional, Szczęsna, A., additional, De Castro, J., additional, Garcia Campelo, M.R., additional, Hernández, A., additional, Moran, T., additional, Provencio, M., additional, Dasgupta, A., additional, Gabrail, N., additional, Harshad, A., additional, Liu, S., additional, Oubre, D., additional, Panikkar, R., additional, and Sanborn, R., additional

Published
2023
Full Text
View/download PDF

11. A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors

Author

Soria, J.C., Gan, H.K., Blagden, S.P., Plummer, R., Arkenau, H.T., Ranson, M., Evans, T.R.J., Zalcman, G., Bahleda, R., Hollebecque, A., Lemech, C., Dean, E., Brown, J., Gibson, D., Peddareddigari, V., Murray, S., Nebot, N., Mazumdar, J., Swartz, L., Auger, K.R., Fleming, R.A., Singh, R., and Millward, M.

Published
2016
Full Text
View/download PDF

12. Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial

Author

Westeel, V., Poudenx, M., Mazieres, J., Martinet, Y., Gury, J-P., Baize, N., Dumont, P., Vaylet, F., Foucher, P., Dauba, J., Tredaniel, J., Laize, H., Petit, L., Coëtmeur, D., Doubre, H., Pichon, E., Schneider, S., Goutorbe, F., Gervais, R., Zaegel, M., Dehette, S., Coudert, B., Duhamel, J-P., Dixmier, A., Thiberville, L., Deguiral, P., Monnot, H., Romand, P., Berard, H., Raspaud, C., Pujol, J.-L., Lavole, A., Quoix, E., Molinier, O., Souquet, P.-J., Barlesi, F., Le Caer, H., Moro-Sibilot, D., Fournel, P., Oster, J.P., Chatellain, P., Barre, P., Jeannin, G., Mourlanette, P., Derollez, M., Herman, D., Renault, A., Dayen, C., Lamy, P.J., Langlais, A., Morin, F., and Zalcman, G.

Published
2015
Full Text
View/download PDF

13. 4P FDG PET derived metabolic tumor volume (MTV) and its transcriptomic correlates as biomarker to predict efficacy of immune checkpoint inhibitors (ICB) alone or in combination with chemotherapy in advanced NSCLC: A multicentric study

Author

Dall'Olio, F.G., primary, Garcia, C.A., additional, Zrafi, W.S., additional, Fortunati, E., additional, Bettayeb, A., additional, Zalcman, G., additional, Remon Masip, J., additional, Hendriks, L., additional, Tagliamento, M., additional, Bonardel, G., additional, Helissey, C., additional, Roelants, V., additional, Fourquet, A., additional, Aboubakar, F., additional, Chaput-Gras, N., additional, Passiglia, F., additional, Monnet, I., additional, Planchard, D., additional, Barlesi, F., additional, and Besse, B., additional

Published
2022
Full Text
View/download PDF

14. 259MO A predictive score of cancer immunotherapy responses based on ecological analysis of gut microbiota

Author

Derosa, L., primary, Alves Costa Silva, C., additional, Iebba, V., additional, Routy, B., additional, Reni, A., additional, Audigier-Valette, C., additional, Zalcman, G., additional, Mazieres, J., additional, Friard, S., additional, Goldwasser, F., additional, Moro-Sibilot, D., additional, Scherpereel, A., additional, Pegliasco, H., additional, Martinez, S., additional, Escudier, B., additional, Planchard, D., additional, Albiges, L., additional, Besse, B., additional, Barlesi, F., additional, and Zitvogel, L., additional

Published
2022
Full Text
View/download PDF

16. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network

Author

Beau-Faller, M., Prim, N., Ruppert, A.-M., Nanni-Metéllus, I., Lacave, R., Lacroix, L., Escande, F., Lizard, S., Pretet, J.-L., Rouquette, I., de Crémoux, P., Solassol, J., de Fraipont, F., Bièche, I., Cayre, A., Favre-Guillevin, E., Tomasini, P., Wislez, M., Besse, B., Legrain, M., Voegeli, A.-C., Baudrin, L., Morin, F., Zalcman, G., Quoix, E., Blons, H., and Cadranel, J.

Published
2014
Full Text
View/download PDF

17. LBA71 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (uMPM): 4-year update from CheckMate 743

Author

Zalcman, G., primary, Oulkhouir, Y., additional, Cornelissen, R., additional, Greillier, L., additional, Cid, J.R. Rodriguez, additional, Mazieres, J., additional, Briggs, P., additional, Nowak, A.K., additional, Tsao, A., additional, Fujimoto, N., additional, Peters, S., additional, Mansfield, A.S., additional, Popat, S., additional, Nassar, A., additional, Bushong, J., additional, Hu, N., additional, Spires, T., additional, Balli, D., additional, Eccles, L., additional, and Baas, P., additional

Published
2022
Full Text
View/download PDF

18. 972O Nivolumab (Nivo) plus ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced non-small cell lung cancer (aNSCLC): Results of the randomized IFCT-1701 phase III trial

Author

Zalcman, G., primary, Madroszyk Flandin, A-C., additional, Molinier, O., additional, Dayen, C., additional, Egenod, T., additional, Debieuvre, D., additional, Beaucaire-Danel, S., additional, Dixmier, A., additional, Pichon, E., additional, Galland Girodet, S., additional, Giroux-Leprieur, E., additional, Cloarec, N., additional, Cadranel, J., additional, Otto, J., additional, Romand, P., additional, Langlais, A., additional, Morin, F., additional, Antoine, M., additional, Westeel, V., additional, and Toffart, A.C., additional

Published
2022
Full Text
View/download PDF

19. 1661MO Genomic somatic copy number alterations drive adaptive tumor immune suppression and primary resistance to anti-PD1 + anti-angiogenics in pleural mesothelioma

Author

Danlos, F-X, primary, Baldini, C., additional, Texier, M., additional, Varga, A., additional, Mouraud, S., additional, Job, B., additional, Letourneur, D., additional, Cassard, L., additional, Bredel, D., additional, Laghouati, S., additional, Adam, J., additional, Droin, N., additional, Parpaleix, A., additional, Chaput-Gras, N., additional, Rabeau, A., additional, Massard, C., additional, Soria, J-C., additional, Zalcman, G., additional, Planchard, D., additional, and Marabelle, A., additional

Published
2022
Full Text
View/download PDF

20. From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the french intergroup (IFCT) and the groupe d'Oncologie de langue française (GOLF)

Author

Couraud, S., Cortot, A.B., Greillier, L., Gounant, V., Mennecier, B., Girard, N., Besse, B., Brouchet, L., Castelnau, O., Frappé, P., Ferretti, G.R., Guittet, L., Khalil, A., Lefebure, P., Laurent, F., Liebart, S., Molinier, O., Quoix, E., Revel, M.-P., Stach, B., Souquet, P.-J., Thomas, P., Trédaniel, J., Lemarié, E., Zalcman, G., Barlési, F., and Milleron, B.

Published
2013
Full Text
View/download PDF

21. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma:3-year outcomes from CheckMate 743

Author

Peters, S., Scherpereel, A., Cornelissen, R., Oulkhouir, Y., Greillier, L., Kaplan, M. A., Talbot, T., Monnet, I., Hiret, S., Baas, P., Nowak, A. K., Fujimoto, N., Tsao, A. S., Mansfield, A. S., Popat, S., Zhang, X., Hu, N., Balli, D., Spires, T., Zalcman, G., Peters, S., Scherpereel, A., Cornelissen, R., Oulkhouir, Y., Greillier, L., Kaplan, M. A., Talbot, T., Monnet, I., Hiret, S., Baas, P., Nowak, A. K., Fujimoto, N., Tsao, A. S., Mansfield, A. S., Popat, S., Zhang, X., Hu, N., Balli, D., Spires, T., and Zalcman, G.

Abstract

Background: In the phase III CheckMate 743 study (NCT02899299), first-line nivolumab plus ipilimumab significantly improved overall survival (OS) versus chemotherapy in patients with unresectable malignant pleural mesothelioma (MPM). We report updated data with 3-year minimum follow-up. Patients and methods: Adults with previously untreated, histologically confirmed, unresectable MPM and Eastern Cooperative Oncology Group performance status of ≤1 were randomized 1: 1 to nivolumab (3 mg/kg every 2 weeks) plus ipilimumab (1 mg/kg every 6 weeks) for up to 2 years, or six cycles of platinum plus pemetrexed chemotherapy. This report includes updated efficacy and safety outcomes, exploratory biomarker analyses including four-gene inflammatory expression signature score, and a post hoc efficacy analysis in patients who discontinued treatment due to treatment-related adverse events (TRAEs). Results: With a median follow-up of 43.1 months, nivolumab plus ipilimumab continued to prolong OS versus chemotherapy. Median OS was 18.1 versus 14.1 months [hazard ratio (95% confidence interval), 0.73 (0.61–0.87)], and 3-year OS rates were 23% versus 15%, respectively. Three-year progression-free survival rates were 14% versus 1%, and objective response rates were 40% versus 44%. At 3 years, 28% versus 0% of responders had an ongoing response. Improved survival benefit with nivolumab plus ipilimumab versus chemotherapy was observed across subgroups, including histology. A high score of the four-gene inflammatory signature appeared to correlate with improved survival benefit with nivolumab plus ipilimumab. No new safety signals were observed with nivolumab plus ipilimumab, despite patients being off therapy for 1 year. In patients who discontinued nivolumab plus ipilimumab due to TRAEs, median OS was 25.4 months, and 34% of responders maintained their responses for ≥3 years after discontinuation. Conclusions: With 3 years’ minimum follow-up, nivolumab plus ipilimumab continued to pr

Published
2022

23. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial

Author

Peters, S., primary, Pujol, J.-L., additional, Dafni, U., additional, Dómine, M., additional, Popat, S., additional, Reck, M., additional, Andrade, J., additional, Becker, A., additional, Moro-Sibilot, D., additional, Curioni-Fontecedro, A., additional, Molinier, O., additional, Nackaerts, K., additional, Insa Mollá, A., additional, Gervais, R., additional, López Vivanco, G., additional, Madelaine, J., additional, Mazieres, J., additional, Faehling, M., additional, Griesinger, F., additional, Majem, M., additional, González Larriba, J.L., additional, Provencio Pulla, M., additional, Vervita, K., additional, Roschitzki-Voser, H., additional, Ruepp, B., additional, Mitchell, P., additional, Stahel, R.A., additional, Le Pechoux, C., additional, De Ruysscher, D., additional, Stahel, R., additional, Hiltbrunner, A., additional, Pardo-Contreras, M., additional, Gasca-Ruchti, A., additional, Giacomelli, N., additional, Kammler, R., additional, Marti, N., additional, Pfister, R., additional, Piguet, A.C., additional, Roux, S., additional, Troesch, S., additional, Schneider, M., additional, Schweri, R., additional, Zigomo, I., additional, Tsourti, Z., additional, Zygoura, P., additional, Tsouprou, S., additional, Kassapian, M., additional, Dimopoulou, G., additional, Andriakopoulou, C., additional, Morin, F., additional, Amour, E., additional, Mariaule, G., additional, Archirel, N., additional, Fernandez, M., additional, Pereira, E., additional, Benito, L., additional, Lopez, K., additional, Hernández, A., additional, Chinchen, S., additional, Jurkovic, H., additional, Livingstone, A., additional, Mitchell, J., additional, Walker, M., additional, Ng, S., additional, Steer, C., additional, Briscoe, K., additional, Saqib, A., additional, Abdi, E., additional, Houghton, B., additional, O’Byrne, K., additional, Chittajallu, B.R., additional, Hughes, B.G., additional, Black, A., additional, Werner, H., additional, Zalcman, G., additional, Vaylet, F., additional, Merle, P., additional, Monnet, I., additional, Girard, N., additional, Souquet, P.-J., additional, Barlesi, F., additional, Debieuvre, D., additional, Senellart, H., additional, Poudenx, M., additional, Dixmier, A., additional, Pouessel, D., additional, Cadranel, J., additional, Lena, H., additional, Quoix, E., additional, Friard, S., additional, Audigier-Valette, C., additional, Pichon, E., additional, Kokowski, K., additional, Kirchen, H., additional, Tufman, A., additional, De-Colle, C., additional, de Langen, J., additional, Insa, A., additional, Massutí, B., additional, Pulla, M.P., additional, Aix, S.P., additional, Villanueva, N., additional, Vivanco, G.L., additional, Franks, K., additional, and Califano, R., additional

Published
2022
Full Text
View/download PDF

25. Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial†

Author

Pujol, J.-L., Lavole, A., Quoix, E., Molinier, O., Souquet, P.-J., Barlesi, F., Le Caer, H., Moro-Sibilot, D., Fournel, P., Oster, J. P., Chatellain, P., Barre, P., Jeannin, G., Mourlanette, P., Derollez, M., Herman, D., Renault, A., Dayen, C., Lamy, P. J., Langlais, A., Morin, F., Zalcman, G., Westeel, V., Poudenx, M., Mazieres, J., Martinet, Y., Gury, J-P., Baize, N., Dumont, P., Vaylet, F., Foucher, P., Dauba, J., Tredaniel, J., Laize, H., Petit, L., Coëtmeur, D., Doubre, H., Pichon, E., Schneider, S., Goutorbe, F., Gervais, R., Zaegel, M., Dehette, S., Coudert, B., Duhamel, J-P., Dixmier, A., Thiberville, L., Deguiral, P., Monnot, H., Romand, P., Berard, H., and Raspaud, C.

Published
2015
Full Text
View/download PDF

26. 1172MO Durvalumab consolidation in patients with stage III non-resecable NSCLC with driver genomic alterations

Author

Melia, M. Riudavets, primary, Auclin, E., additional, Lamas, M.A. Mosteiro, additional, Dempsey, N., additional, Majem, M., additional, Lobefaro, R., additional, Castro, R. Lopez, additional, Barrera, J. Bosch, additional, Pilotto, S., additional, Martín, E. Escalera, additional, Tagliamento, M., additional, Martinez, J. Mosquera, additional, Zalcman, G., additional, Nadal, E., additional, Lopes, G., additional, Signorelli, D., additional, Campelo, M.R. Garcia, additional, Besse, B., additional, Planchard, D., additional, and Mezquita, L., additional

Published
2021
Full Text
View/download PDF

27. 1732MO Pembrolizumab and nintedanib for patients with advanced mesothelioma

Author

Danlos, F-X., primary, Baldini, C., additional, Varga, A., additional, Mouraud, S., additional, Job, B., additional, Letourneur, D., additional, Cassard, L., additional, Bredel, D., additional, Laghouati, S., additional, Texier, M., additional, Adam, J., additional, Droin, N., additional, Parpaleix, A., additional, Chaput, N., additional, Rabeau, A., additional, Zalcman, G., additional, Planchard, D., additional, Massard, C., additional, Soria, J-C., additional, and Marabelle, A., additional

Published
2021
Full Text
View/download PDF

28. 1151MO Pathological response is an independent factor of overall survival and disease-free survival after neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase II trial

Author

Wislez, M., primary, Mazieres, J., additional, Lavole, A., additional, Zalcman, G., additional, Carre, O., additional, Egenod, T., additional, Caliandro, R., additional, Gervais, R., additional, Jeannin, G., additional, Molinier, O., additional, Massiani, M-A., additional, Langlais, A., additional, Morin, F., additional, Le Pimpec Barthes, F., additional, Brouchet, L., additional, Assouad, J., additional, Milleron, B., additional, Westeel, V., additional, Antoine, M., additional, and Damotte, D., additional

Published
2021
Full Text
View/download PDF

29. 1170O An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Characterisation of PORT efficacy in lung ART (IFCT-0503, UK NCRI, SAKK)

Author

Le Pechoux, C., primary, Barlesi, F., additional, Pourel, N., additional, Faivre-Finn, C., additional, Lerouge, D., additional, Zalcman, G., additional, Antoni, D., additional, Lamezec, B., additional, Nestle, U., additional, Boisselier, P., additional, Thillays, F., additional, Paumier, A., additional, Dansin, E., additional, Peignaux, K., additional, Madelaine, J., additional, Pichon, E., additional, Larrouy, A., additional, Riesterer, O., additional, Lavolle, A., additional, and Bardet, A., additional

Published
2021
Full Text
View/download PDF

30. 1341P NRAS mutated non-small cell lung cancer (NSCLC) patients: Characteristics and outcomes

Author

Dehem, A., primary, Mazieres, J., additional, Chour, A., additional, Guisier, F., additional, Ferreira, M., additional, Boussageon, M., additional, Girard, N., additional, Moro-Sibilot, D., additional, Cadranel, J., additional, Zalcman, G., additional, Ricordel, C., additional, Wislez, M., additional, Munck, C., additional, Poulet, C-H., additional, Gauvain, C., additional, Descarpentries, C., additional, Wasielewski, E., additional, Cortot, A.B., additional, and Baldacci, S., additional

Published
2021
Full Text
View/download PDF

31. LBA65 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743

Author

Peters, S., primary, Scherpereel, A., additional, Cornelissen, R., additional, Oulkhouir, Y., additional, Greillier, L., additional, Kaplan, M.A., additional, Talbot, T., additional, Monnet, I., additional, Hiret, S., additional, Baas, P., additional, Nowak, A.K., additional, Fujimoto, N., additional, Tsao, A.S., additional, Mansfield, A.S., additional, Popat, S., additional, Zhang, X., additional, Hu, N., additional, Balli, D., additional, Sanzari, J., additional, and Zalcman, G., additional

Published
2021
Full Text
View/download PDF

32. 1291O Radiotherapy boost to 74 Gy based on FDG-PET at 42 Gy of radiochemotherapy (RCT) in patients with inoperable stage III non-small cell lung cancer (RTEP7 – IFCT 1401): A prospective multicentre, open-label, randomised, controlled trial

Author

Vera, P., Le Tinier, F., Chaumet-Riffaud, P., Martin, E., Pourel, N., Boisselier, P., Salem, N., Le Pechoux, C., Giroux-Leprieur, E., Guillerm, S., Valette, C. Audigier, Lerouge, D., Massabeau, C., Moisson, P., Larrouy, A., Hapdey, S., Langlais, A., Amour, E., Zalcman, G., Giraud, P., and Thureau, S.

Published
2023
Full Text
View/download PDF

33. LBA1 First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient-reported outcomes (PROs) from CheckMate 743

Author

Scherpereel, A., primary, Antonia, S., additional, Bautista, Y., additional, Grossi, F., additional, Kowalski, D., additional, Zalcman, G., additional, Nowak, A., additional, Fujimoto, N., additional, Peters, S., additional, Tsao, A., additional, Mansfield, A., additional, Popat, S., additional, Sun, X., additional, Padilla, B., additional, Aanur, P., additional, Daumont, M., additional, Bennett, B., additional, McKenna, M., additional, and Baas, P., additional

Published
2020
Full Text
View/download PDF

35. ID:2908 First-Line Nivolumab + Ipilimumab vs Chemotherapy in Unresectable Malignant Pleural Mesothelioma: CheckMate 743

Author

Baas, P., primary, Scherpereel, A., additional, Nowak, A., additional, Fujimoto, N., additional, Peters, S., additional, Tsao, A., additional, Mansfield, A., additional, Popat, S., additional, Jahan, T., additional, Antonia, S., additional, Oulkhouir, Y., additional, Bautista, Y., additional, Cornelissen, R., additional, Greillier, L., additional, Grossi, F., additional, Kowalski, D.M., additional, Rodriguez-Cid, J., additional, Aanur, P., additional, Baudelet, C., additional, and Zalcman, G., additional

Published
2020
Full Text
View/download PDF

36. 1349P Lorlatinib for advanced ROS1+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort

Author

Girard, N., primary, Girodet, S. Galland, additional, Duruisseaux, M., additional, Avrillon, V., additional, Roch, B., additional, Otto, J., additional, Cadranel, J., additional, Coudurier, M., additional, Moro-Sibilot, D., additional, Egenod, T., additional, Lamy, R., additional, Bennouna, J., additional, Zalcman, G., additional, Ricordel, C., additional, Tillon, J., additional, Odier, L., additional, Besse, B., additional, Missy, P., additional, Westeel, V., additional, and Baldacci, S., additional

Published
2020
Full Text
View/download PDF

37. 1673MO The GCO-002 CACOVID-19 cohort: A French nationwide multicenter study of COVID-19 infected cancer patients and consequences on cancer management

Author

Lièvre, A., primary, Turpin, A., additional, Ray-Coquard, I.L., additional, Le Malicot, K., additional, Thariat, J., additional, Ahle, G., additional, Mathieu, R., additional, Sebbagh, V., additional, Debieuvre, D., additional, Canellas, A., additional, Garcia-Larnicol, M-L., additional, Colle, R., additional, Hardy-Bessard, A-C., additional, Mansi, L., additional, Bourhis, J., additional, Gorphe, P., additional, Ursu, R., additional, IDBAIH Ahmed, A., additional, Zalcman, G., additional, and Bouche, O., additional

Published
2020
Full Text
View/download PDF

39. LBA3_PR An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement: Primary end-point analysis of LungART (IFCT-0503, UK NCRI, SAKK) NCT00410683

Author

Le Pechoux, C., primary, Pourel, N., additional, Barlesi, F., additional, Faivre-Finn, C., additional, Lerouge, D., additional, Zalcman, G., additional, Antoni, D., additional, Lamezec, B., additional, Nestle, U., additional, Boisselier, P., additional, Thillays, F., additional, Paumier, A., additional, Dansin, E., additional, Peignaux, K., additional, Madelaine, J., additional, Pichon, E., additional, Larrouy, A., additional, Riesterer, O., additional, Lavole, A., additional, and Bardet, A., additional

Published
2020
Full Text
View/download PDF

40. 1214O Neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): Preliminary results from a multicenter study (IFCT-1601 IONESCO)

Author

Wislez, M., primary, Mazieres, J., additional, Lavole, A., additional, Zalcman, G., additional, Carre, O., additional, Egenod, T., additional, Caliandro, R., additional, Gervais, R., additional, Jeannin, G., additional, Molinier, O., additional, Massiani, M.A., additional, Langlais, A., additional, Morin, F., additional, Le Pimpec Barthes, F., additional, Brouchet, L., additional, Assouad, J., additional, Milleron, B., additional, Damotte, D., additional, Antoine, M., additional, and Westeel, V., additional

Published
2020
Full Text
View/download PDF

43. IFCT-1701 DICIPLE: A randomized phase III trial comparing continuation nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in patients with PDL1-positive stage IV non-small cell lung cancer (NSCLC) after nivolumab-ipilimumab induction treatment

Author

Zalcman, G., primary, Toffart, A.C., additional, Madroszyk Flandin, A.-C., additional, Molinier, O., additional, Dayen, C., additional, Egenod, T., additional, Dixmier, A., additional, Giroux Leprieur, E., additional, Masson, P., additional, Cloarec, N., additional, Thibonnier, L., additional, Favier, L., additional, Debieuvre, D., additional, Mazieres, J., additional, Van Hulst, S., additional, Pichon, E., additional, Amour, E., additional, Morin, F., additional, and Souquet, P.-J., additional

Published
2019
Full Text
View/download PDF

44. MA05.11 Safety and Efficacy of Nintedanib in Combination with Pembrolizumab in Patients with Refractory/Relapsing Malignant Pleural Mesothelioma

Author

Varga, A., primary, Zalcman, G., additional, Gomez-Roca, C., additional, Ammari, S., additional, Caramella, C., additional, Gounant, V., additional, Rabeau, A., additional, Paoletti, X., additional, Baldini, C., additional, Martin-Romano, P., additional, Champiat, S., additional, Vuagnat, P., additional, Michot, J., additional, Mezquita, L., additional, Massard, C., additional, Besse, B., additional, Soria, J.C., additional, Marabelle, A., additional, and Planchard, D., additional

Published
2019
Full Text
View/download PDF

45. MA05.05 Post-Discontinuation Treatments in IFCT-GFPC-0701 MAPS Trial: Real-World Effectiveness of 2nd-Line (2L) Treatments for Mesothelioma

Author

Zalcman, G., primary, Brosseau, S., additional, Mazieres, J., additional, Margery, J., additional, Greillier, L., additional, Audigier-Valette, C., additional, Moro-Sibilot, D., additional, Molinier, O., additional, Corre, R., additional, Monnet, I., additional, Gounant, V., additional, Rivière, F., additional, Gervais, R., additional, Janicot, H., additional, Locher, C., additional, Langlais, A., additional, Parienti, J., additional, Morin, F., additional, and Scherpereel, A., additional

Published
2019
Full Text
View/download PDF

46. Second/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD)

Author

Zalcman, G., primary, Mazieres, J., additional, Greillier, L., additional, Brosseau, S., additional, Lantuejoul, S., additional, Do, P., additional, Bylicki, O., additional, Monnet, I., additional, Corre, R., additional, Audigier-Valette, C., additional, Locatelli-Sanchez, M., additional, Molinier, O., additional, Guisier, F., additional, Urban, T., additional, Planchard, D., additional, Ligeza-Poisson, C., additional, Amour, E., additional, Morin, F., additional, Moro-Sibilot, D., additional, and Scherpereel, A., additional

Published
2019
Full Text
View/download PDF

47. MA07.02 Early Change of dNLR Is Correlated with Outcomes in Advanced NSCLC Patients Treated with Immunotherapy

Author

Mezquita, L., primary, Preeshagul, I., additional, Auclin, E., additional, Saravia, D., additional, Hendriks, L., additional, Rizvi, H., additional, Planchard, D., additional, Park, W., additional, Nadal, E., additional, Ruffinelli, J.C., additional, Ponce, S., additional, Audigier-Valette, C., additional, Carnio, S., additional, Novello, S., additional, Zalcman, G., additional, Majem, M., additional, Mariniello, A., additional, Dingemans, A.M., additional, Lopes, G., additional, Rossoni, C., additional, Pignon, J., additional, Chaput, N., additional, Hellmann, M., additional, Arbour, K., additional, and Besse, B., additional

Published
2019
Full Text
View/download PDF

48. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

Author

Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A.B., Mezquita, L., Thai, A.A., Mascaux, C., Couraud, S., Veillon, R., Heuvel, M. van den, Neal, J., Peled, N., Fruh, M., Ng, T.L., Gounant, V., Popat, S., Diebold, J., Sabari, J., Zhu, V.W., Rothschild, S.I., Bironzo, P., Martinez-Marti, A., Curioni-Fontecedro, A., Rosell, R., Lattuca-Truc, M., Wiesweg, M., Besse, B. de, Solomon, B., Barlesi, F., Schouten, R.D., Wakelee, H., Camidge, D.R., Zalcman, G., Novello, S., Ou, S.I., Milia, J., Gautschi, O., Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A.B., Mezquita, L., Thai, A.A., Mascaux, C., Couraud, S., Veillon, R., Heuvel, M. van den, Neal, J., Peled, N., Fruh, M., Ng, T.L., Gounant, V., Popat, S., Diebold, J., Sabari, J., Zhu, V.W., Rothschild, S.I., Bironzo, P., Martinez-Marti, A., Curioni-Fontecedro, A., Rosell, R., Lattuca-Truc, M., Wiesweg, M., Besse, B. de, Solomon, B., Barlesi, F., Schouten, R.D., Wakelee, H., Camidge, D.R., Zalcman, G., Novello, S., Ou, S.I., Milia, J., and Gautschi, O.

Abstract

Contains fulltext : 215810.pdf (publisher's version ) (Closed access), BACKGROUND: Anti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely used to treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of ICI across NSCLC harboring oncogenic alterations is poorly characterized. The aim of our study was to address the efficacy of ICI in the context of oncogenic addiction. PATIENTS AND METHODS: We conducted a retrospective study for patients receiving ICI monotherapy for advanced NSCLC with at least one oncogenic driver alteration. Anonymized data were evaluated for clinicopathologic characteristics and outcomes for ICI therapy: best response (RECIST 1.1), progression-free survival (PFS), and overall survival (OS) from ICI initiation. The primary end point was PFS under ICI. Secondary end points were best response (RECIST 1.1) and OS from ICI initiation. RESULTS: We studied 551 patients treated in 24 centers from 10 countries. The molecular alterations involved KRAS (n = 271), EGFR (n = 125), BRAF (n = 43), MET (n = 36), HER2 (n = 29), ALK (n = 23), RET (n = 16), ROS1 (n = 7), and multiple drivers (n = 1). Median age was 60 years, gender ratio was 1 : 1, never/former/current smokers were 28%/51%/21%, respectively, and the majority of tumors were adenocarcinoma. The objective response rate by driver alteration was: KRAS = 26%, BRAF = 24%, ROS1 = 17%, MET = 16%, EGFR = 12%, HER2 = 7%, RET = 6%, and ALK = 0%. In the entire cohort, median PFS was 2.8 months, OS 13.3 months, and the best response rate 19%. In a subgroup analysis, median PFS (in months) was 2.1 for EGFR, 3.2 for KRAS, 2.5 for ALK, 3.1 for BRAF, 2.5 for HER2, 2.1 for RET, and 3.4 for MET. In certain subgroups, PFS was positively associated with PD-L1 expression (KRAS, EGFR) and with smoking status (BRAF, HER2). CONCLUSIONS: : ICI induced regression in some tumors with actionable driver alterations, but clinical activity was lower compared with the KRAS group and the lack of response in the ALK group was notable. Patients with actionable tumo

Published
2019

49. Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations : New Results from the Global IMMUNOTARGET Registry

Author

Gautschi, O., Drilon, A., Milia, J., Lusque, A., Mhanna, L., Li, B., Sabari, J., Cortot, A., Besse, B., Mezquita, L., Solomon, B., Thai, A., Couraud, S., Veilion, R., Mascaux, C., Barlesi, F., Van den Heuvel, M., Schouten, R., Wakelee, H., Mah, A., Camidge, D. R., Ng, T., Peled, N., Lilach, Y., Popat, S., Ou, S., Zhu, V., Velcheti, V., Fontecedro, A. C., Akhoundova, D., Fruh, M., Zalcman, G., Gounant, V., Novello, S., Bironzo, P., Felip, E., Martinez-Marti, A., Moro-Sibilot, D., Rosell, R., Karachaliou, N., Schuler, Martin, Wiesweg, Marcel, Diebold, J., and Mazieres, J.

Subjects
Medizin
Published
2018

Catalog

Books, media, physical & digital resources
See catalog results